Literature DB >> 3481332

Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae.

P M Shah1, V Schäfer, T Hubener, C Metz, W Stille.   

Abstract

Ofloxacin is highly active against Gram-negative aerobic bacilli, but moderately active against Gram-positive cocci. The minimal inhibitory concentrations (MICs) against Streptococcus pneumoniae range between 1 and 2 mg/L. MICs of roxithromycin (RU 28965) against S. pneumoniae range between 0.004 and 0.03 mg/L, but Gram-negative bacilli are resistant. The bactericidal activities of ofloxacin and roxithromycin were evaluated against 15 strains of S. pneumoniae, which were isolated recently from clinical specimens. Killing activity was evaluated under conditions simulating serum pharmacokinetic parameters. Initial concentrations were 10 mg/L for roxithromycin and 2 mg/L for ofloxacin, and the half-life was 6 hours for both compounds. Under these conditions, roxithromycin was rapidly bactericidal. The speed at which pneumococci were killed was faster with roxithromycin than with ofloxacin. No regrowth was seen with roxithromycin, but regrowth occurred in 8 of 15 strains with ofloxacin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481332     DOI: 10.2165/00003495-198700341-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  4 in total

1.  An experimental model for the study of the antibacterial activity of the sulfonamides.

Authors:  A Sanfilippo; E Morvillo
Journal:  Chemotherapia (Basel)       Date:  1968

2.  An improved method to study antibacterial activity of antibiotics in an in vitro model simulating serum levels.

Authors:  P M Shah
Journal:  Methods Find Exp Clin Pharmacol       Date:  1980-08

3.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

4.  [Respiratory tract infections--clinical results with ofloxacin].

Authors:  P M Shah; H Knothe
Journal:  Infection       Date:  1986       Impact factor: 3.553

  4 in total
  1 in total

Review 1.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.